English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Metoprolol is a lipophilic beta(1) selective adrenergic receptor antagonist used in antihypertensive therapy. It is metabolized by the protein product of the cytochrome P450 2D6 (CYP2D6) gene. Few studies have been performed on the association between the beta(1) adrenoreceptor, CYP2D6 polymorphism and blood pressure. The one reported here is a prospective, observational, clinical study in Chinese Han hypertensive patients on the combined influences of CYP2D6 and beta(1) adrenoreceptor polymorphisms on the therapeutic effects of metoprolol in 300 out-patients with essential hypertension. The same dose of metoprolol achieved different therapeutic effects in patients with different CYP2D6 and beta(1) adrenoreceptor polymorphisms. Additionally, different doses of metoprolol could achieve the same therapeutic effects in patients with different CYP2D6 and beta(1) adrenoreceptor polymorphisms. Knowledge of the combination of CYP2D6 and beta(1) adrenoreceptor polymorphisms may be used to guide antihypertensive therapy using beta(1) adrenoreceptor antagonists.

Effects of Polymorphism of the β1Adrenoreceptor andCYP2D6on the Therapeutic Effects of Metoprolol

Effects of Polymorphism of the β₁Adrenoreceptor andCYP2D6on the Therapeutic Effects of Metoprolol